Segment Reporting - Schedule of Research and Development Expenses (Details) - Research and Development Activities Segment - USD ($) |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2025 |
Sep. 30, 2024 |
Sep. 30, 2025 |
Sep. 30, 2024 |
|
| Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items] | ||||
| External clinical development expenses | $ 6,897,753 | $ 3,517,499 | $ 23,538,634 | $ 7,330,409 |
| Personnel related and stock-based compensation | 1,495,889 | 1,108,889 | 4,241,662 | 2,765,541 |
| Other research and development expenses | 963,802 | 256,949 | 3,112,158 | 812,588 |
| Total research and development expenses | 9,357,444 | 4,883,337 | 30,892,454 | 10,908,538 |
| SBI-100 | ||||
| Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items] | ||||
| External clinical development expenses | 8,270 | 110,580 | 10,511 | 2,118,397 |
| nimacimab | ||||
| Segment, Reconciliation of Other Items from Segments to Consolidated [Line Items] | ||||
| External clinical development expenses | $ 6,889,483 | $ 3,406,919 | $ 23,528,123 | $ 5,212,012 |